News

ATOLL Shows IV Enoxaparin Improves Ischemic Outcomes in Primary PCI for STEMI

Publish date: September 3, 2010

 

The ATOLL study was sponsored by Assistance Publique-Hôpitaux de Paris with the help of a research grant from Sanofi-Aventis. Dr. Montalescot disclosed that he has received consulting and/or lecture fees from Sanofi-Aventis as well as more than a dozen others.

Pages

Recommended Reading

Study: Aliskiren Dual Therapy Beats Amlodipine for Blood Pressure Control in Blacks
MDedge Internal Medicine
Menstrual Phase Matters When Measuring CRP Levels to Gauge CVD Risk
MDedge Internal Medicine
CDC: U.S. Adult Obesity Rates Rose Again in 2009
MDedge Internal Medicine
Triglyceride Content of HDL Predicts Statin Myotoxicity
MDedge Internal Medicine
Heart Rate Cut With Ivabradine, Trims Heart Failure Deaths in Phase III Study
MDedge Internal Medicine
Stent Thrombosis Occurs More Often in Blacks
MDedge Internal Medicine
45,000-Patient Registry Yields Atherothrombotic Disease Risk Factors
MDedge Internal Medicine
Intensive BP Control Slows CKD Progression Only in Select Patients
MDedge Internal Medicine
Long-Term Sibutramine Use Linked to Nonfatal Strokes and MIs
MDedge Internal Medicine
AVERROES: Apixaban Bests Aspirin for Stroke Reduction in AF
MDedge Internal Medicine